Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.34200
Abstract: Key Points Question What is the comparative effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) antagonists for older patients with inflammatory bowel diseases (IBDs)? Findings In a comparative effectiveness study of 754 older… read more here.
Keywords: necrosis factor; safety; vedolizumab tumor; tumor necrosis ... See more keywords
Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030590
Abstract: Background: Vedolizumab is a humanized monoclonal antibody that inhibits gut-selective α4β7 integrins on the surface of leukocytes, preventing their trafficking into the gastrointestinal tract, and ultimately achieves the effect of suppressing intestinal inflammation. This study… read more here.
Keywords: vedolizumab; inflammatory bowel; analysis; safety vedolizumab ... See more keywords
Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
Sign Up to like & getrecommendations! Published in 2025 at "BMC Gastroenterology"
DOI: 10.1186/s12876-025-04125-1
Abstract: Limited data exist regarding the efficacy and safety of vedolizumab (VDZ) in China’s elderly adult population with ulcerative colitis (UC) in China. In this investigation, a comparative analysis of its efficacy and safety was performed… read more here.
Keywords: elderly younger; adult; safety vedolizumab; efficacy safety ... See more keywords